Pharmacyclics (PCYC) – Hot FDA News
-
Pharmacyclics (PCYC) Reports IMBRUVICA Combo Phase 3 Met Primary Endpoint in CLL, SLL; Study Will be Unblinded
-
FDA Approves Imbruvica to Treat Chronic Lymphocytic Leukemia (PCYC)
-
-
-
Back to PCYC Stock Lookup